BLTE BELITE BIO INC

Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results

Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results

SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, will host a conference call on Thursday, August 11, 2022, at 4:30 p.m. Eastern time to discuss the Company’s financial results for the first half, ended June 30, 2022, and provide a corporate progress update. The financial results will be issued in a press release on Wednesday, August 10, 2022.

Belite Bio, Inc First Half 2022 Financial Result Conference Call Information:

Date:Thursday, August 11, 2022
Time:4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Webcast Link:
Phone Registration Link:

Webcast Link Instructions

You can join a live webcast of the conference by visiting the “Webcast” link above or the “Presentations & Events” section of the Company’s Investor Relations website at . A reply will be available approximately two hours after the event for 30 days.

Phone Registration Instructions

To participate in the live call, please register using the “Phone Registration” link above. Once registered, you will receive dial-in numbers and unique PIN numbers via email. At the time of the call, you will dial in using the numbers from the confirmation email, and upon entering the unique PIN, will be routed into the call.

About Belite Bio

Belite Bio is a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, such as atrophic age-related macular degeneration (commonly known as dry AMD) and Stargardt disease, and metabolic diseases. For more information, follow us the Company on , , , or visit us at .

Important Cautions Regarding Forward Looking Statements

This press release contains certain "forward-looking statements" within the meaning of federal securities laws. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about Belite’s beliefs and expectations. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in Belite’s filings with the U.S. Securities and Exchange Commission at . Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Media and Investor Relations Contact:

Jennifer Wu /

Tim McCarthy



EN
01/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BELITE BIO INC

 PRESS RELEASE

Belite Bio Announces Pricing of $350.0 Million Underwritten Public Off...

Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has priced an underwritten public offering of 2,272,727 American Depositary Shares (“ADSs”), each representing one of its ordinary shares, at a public offering price of $154.00 per ADS. The C...

 PRESS RELEASE

Belite Bio Announces Proposed Underwritten Public Offering of American...

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each representing one of its ordinary shares. All of the securities in the offering are to be sold by Belite Bio. In addit...

 PRESS RELEASE

New Hope for People Living with a Disease Once Deemed Untreatable: Bel...

New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033Tinlarebant met the primary efficacy endpoint, demonstrating clinical benefit by significantly reducing the lesion growth rate by 36% compared to placebo, as measured by retinal imagingTinlarebant was ...

 PRESS RELEASE

Belite Bio Reports Third Quarter 2025 Financial Results and Provides a...

Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Completed enrollment with 530 subjects in the pivotal phase 3 PHOENIX trial in geographic atrophy (GA)Completed $15 million registered direct offering and $125 million private placement with potential for up to an additional $165 million upon full warrant exerciseCompleted pivotal phase 3 DRAGON trial in Stargardt disease (STGD); final topline data expected in Q4 2025China’s NMPA has agreed to accept New Drug Application with priority review for Tinlarebant for the treatment of Stargardt disease based on...

 PRESS RELEASE

Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quar...

Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, November 10, 2025, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the third quarter ended September 30, 2025. Webcast InformationDate: Monday, November 10...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch